Biogen | BIIB - Kapitał Własny I Rezerwy





Kapitał Własny I Rezerwy Zmiana Data
AbbVie USD -3.27B 628M 2025-12
Acadia Pharmaceuticals USD 917.27M 94.89M 2025-09
ALKERMES USD 1.82B 85.86M 2025-12
Amgen USD 8.66B 961M 2025-12
Bayer EUR 25.95B 3.75B 2025-12
Biogen USD 18.21B 573.5M 2025-09
BioMarin Pharmaceutical USD 6.09B 30.29M 2025-12
Bristol-Myers Squibb USD 18.55B 1.06B 2025-09
Eli Lilly USD 26.54B 2.74B 2025-12
Esperion Therapeutics USD -301.96M 149.4M 2025-12
Gilead Sciences USD 22.62B 1.16B 2025-12
Incyte USD 5.17B 516.28M 2025-12
Merck USD 51.85B 2.79B 2025-09
Moderna USD 8.65B 680M 2025-12
Neurocrine Biosciences USD 3.25B 249.5M 2025-12
Novartis USD 46.13B 1.38B 2025-12
Pfizer USD 92.8B 4.11B 2025-09
PTC Therapeutics USD -205.31M 49.56M 2025-12
Puma Biotechnology USD 115.27M 10.55M 2025-09
Regeneron Pharmaceuticals USD 31.26B 299.1M 2025-12
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Sanofi EUR 72.81B 1.1B 2026-03
Sanofi EUR 71.71B 14.25B 2025-12
Sarepta Therapeutics USD 1.14B 179.5M 2025-12
Teva Pharmaceutical Industries USD 7.91B 664M 2025-12
Ultragenyx Pharmaceutical USD 9.16M 142.13M 2025-09
United Therapeutics USD 7.1B 506M 2025-12
Vertex Pharmaceuticals USD 18.67B 1.35B 2025-12